The use of a combination comprising or consisting essentially of one or more ancillary compounds and a compound of the formula I, II, III, IV, V, VI, VIa, VII, VIIa or VIIb or any sub groups or examples thereof as defined herein for the manufacture of a medicament for alleviating or reducing the incidence of a disease state or condition mediated by Hsp90 and or glycogen synthase kinase 3 and or cyclin dependent kinases cytotec medication ob